Global Cancer Tissue Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Cancer Tissue Diagnostics Market is presumed to reach the market size of nearly USD 29.88 Billion by 2032 from USD 19.28 Billion in 2023 with a CAGR of 4.99% under the study period 2024-2032.

Cancer tissue diagnostics involves analyzing tissue samples to identify cancerous cells and determine their characteristics, which aids in cancer diagnosis, prognosis, and treatment planning. This process includes various techniques such as histopathology, immunohistochemistry, and molecular diagnostics. Tissue samples, often obtained through biopsy, are examined to detect cancer presence, type, and stage. These diagnostic tests help clinicians understand the genetic and molecular profile of the cancer, allowing for personalized treatment approaches. Advances in diagnostic technologies and the development of targeted therapies have enhanced the accuracy and effectiveness of cancer diagnostics, playing a crucial role in cancer management.

MARKET DYNAMICS

The cancer tissue diagnostics market is propelled by the increasing incidence of cancer globally, combined with a growing emphasis on early & accurate diagnosis. Technological advancements, such as next-generation sequencing & digital pathology, offer improved accuracy and efficiency in cancer diagnostics, creating significant market opportunities. The rising focus on personalized medicine & targeted therapies necessitates detailed molecular and genetic profiling, driving innovation in diagnostic technologies. Additionally, the growing adoption of cancer screening programs and expanding healthcare infrastructure in emerging markets contribute to the growth of the cancer tissue diagnostics market. The integration of artificial intelligence & machine learning in diagnostic processes further enhances capabilities and efficiency, presenting additional opportunities. However, high costs and complex regulatory requirements may restrain cancer tissue diagnostics market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Tissue Diagnostics. The growth and trends of Cancer Tissue Diagnostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Tissue Diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

In Situ Hybridization (ISH) Test Kits (Fluorescent In Situ Hybridization (FISH) Kits, Chromogenic In Situ Hybridization (CISH) Kits)
Molecular Diagnostics Test Kits (Polymerase Chain Reaction (PCR) Kits, Next-Generation Sequencing (NGS) Kits)
Companion Diagnostics Test Kits (Genetic Testing Kits, Biomarker Testing Kits)
Immunohistochemistry (IHC) Test Kits

By Cancer

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Hematologic Cancer
Liver Cancer
Pancreatic Cancer
Skin Cancer (Melanoma)
Others

By End-user

Hospitals
Specialty Centers
Long-term Care Centers
Diagnostic Centers
Academic & Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Tissue Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Tissue Diagnostics market include Abcam Plc, Danaher Corporation, Merck KGaA, Cancer Genetics Inc., Agilent Technologies Inc., Enzo Life Sciences Inc, Abbott, Bio Rad Laboratories Inc., Thermo Fisher Scientific Inc., Exact Science, Biocartis NV, Bio SB, Quidel Corporation, Amoy Diagnostics CO. Ltd., F. Hoffmann-La Roche Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112115540

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER TISSUE DIAGNOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Cancer
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. In Situ Hybridization (ISH) Test Kits (Fluorescent In Situ Hybridization (FISH) Kits, Chromogenic In Situ Hybridization (CISH) Kits) Historic and Forecast Sales By Regions
5.4. Molecular Diagnostics Test Kits (Polymerase Chain Reaction (PCR) Kits, Next-Generation Sequencing (NGS) Kits) Historic and Forecast Sales By Regions
5.5. Companion Diagnostics Test Kits (Genetic Testing Kits, Biomarker Testing Kits) Historic and Forecast Sales By Regions
5.6. Immunohistochemistry (IHC) Test Kits Historic and Forecast Sales By Regions

6. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET ANALYSIS BY CANCER

6.1. Overview By Cancer
6.2. Historical and Forecast Data Analysis By Cancer
6.3. Breast Cancer Historic and Forecast Sales By Regions
6.4. Lung Cancer Historic and Forecast Sales By Regions
6.5. Colorectal Cancer Historic and Forecast Sales By Regions
6.6. Prostate Cancer Historic and Forecast Sales By Regions
6.7. Ovarian Cancer Historic and Forecast Sales By Regions
6.8. Hematologic Cancer Historic and Forecast Sales By Regions
6.9. Liver Cancer Historic and Forecast Sales By Regions
6.10. Pancreatic Cancer Historic and Forecast Sales By Regions
6.11. Skin Cancer (Melanoma) Historic and Forecast Sales By Regions
6.12. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data Analysis By End-user
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Specialty Centers Historic and Forecast Sales By Regions
7.5. Long-term Care Centers Historic and Forecast Sales By Regions
7.6. Diagnostic Centers Historic and Forecast Sales By Regions
7.7. Academic & Research Institutes Historic and Forecast Sales By Regions

8. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER TISSUE DIAGNOSTICS COMPANIES

9.1. Cancer Tissue Diagnostics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CANCER TISSUE DIAGNOSTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abcam Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Danaher Corporation
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Merck KGaA
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Cancer Genetics Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Agilent Technologies Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Enzo Life Sciences Inc
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Abbott
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Bio Rad Laboratories Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Thermo Fisher Scientific Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Exact Science
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Biocartis NV
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Bio SB
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Quidel Corporation
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Amoy Diagnostics CO. Ltd.
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. F. Hoffmann-La Roche Ltd
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies